Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Amyloidosis is caused by extracellular deposition of amyloid protein in various organs and tissues. Light-chain amyloidosis is the most common systemic amyloidosis, whereas transthyretin amyloid cardiomyopathy is emerging as the underdiagnosed variant, especially in the elderly. Cardiac MRI and technetium-99m-pyrophosphate scintigraphy are specific non-invasive modalities that have simplified the diagnostic accuracy of cardiac amyloidosis. Identifying the type of amyloidosis is of paramount importance, given the differences in management protocols. Increased left-ventricular wall thickness and diastolic dysfunction are the most easily detectable manifestations of cardiac amyloidosis. Atrial involvement is early in both light-chain and transthyretin amyloidosis and is associated with high risk of arrhythmias and thromboembolic events. We report a case of wild-type transthyretin amyloid cardiomyopathy with predominant involvement of the right atrium and patchy involvement of the right and left ventricles.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976736 | PMC |
| http://dx.doi.org/10.15420/usc.2024.30 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (I) evuzamitide and Tc-p5+14 (AT-05).
J Nucl Cardiol
August 2025
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.
Systemic amyloidosis is a complex disorder, making early and accurate diagnosis challenging. The most common types are associated with misfolded transthyretin or immunoglobulin light chains, where cardiac and renal amyloidosis portend the worst prognosis. Peptide p5+14 can bind all types of amyloid via multivalent electrostatic interactions.
View Article and Find Full Text PDFVO Max in Clinical Cardiology: Clinical Applications, Evidence Gaps, and Future Directions.
Curr Cardiol Rep
September 2025
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ, USA.
Purpose Of Review: VO₂ max is a fundamental marker of cardiorespiratory fitness with substantial prognostic and diagnostic value within the field of cardiology. This review analyzes current and emerging evidence regarding its clinical uses, highlights key evidence gaps, and explores emerging developments poised to broaden its clinical application.
Recent Findings: Evidence supports VO2 max as a powerful independent predictor for heart failure, coronary artery disease, hypertrophic cardiomyopathy, and cardiac amyloidosis, supporting it use in identifying high-risk patients for advanced interventions.
Echocardiography gets to the heart of cardiac amyloidosis.
Nat Med
September 2025
Department of Internal Medicine with Cardiology and Emergency Medicine, Favoriten Clinic, Wiener Gesundheitsverbund, Vienna, Austria.
Concurrent TTR and AL Amyloidosis: Diagnostic Challenges and Clinical Implications.
JACC Case Rep
September 2025
Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Background: Amyloidosis is a disorder characterized by misfolded protein deposits in organs, often manifesting as cardiac disease.
Case Summary: A 60-year-old male with a history of isolated proteinuria and recent fat biopsy-proven transthyretin (TTR) amyloidosis was referred to us for evaluation of cardiac involvement with amyloidosis. He underwent a technetium pyrophosphate scan which showed Perugini grade 3 uptake concerning for cardiac involvement.
Aortic stenosis: need for treatment of co-existent cardiac amyloidosis?
Eur Heart J
September 2025
Amyloidosis Program, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.